Aude G Chapuis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6976687/publications.pdf

Version: 2024-02-01

22 papers	2,232 citations	471371 17 h-index	713332 21 g-index
22 all docs	22 docs citations	22 times ranked	3599 citing authors

#	Article	IF	Citations
1	Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. Journal of the American Academy of Dermatology, 2018, 78, 457-463.e2.	0.6	346
2	Transferred WT1-Reactive CD8 ⁺ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients. Science Translational Medicine, 2013, 5, 174ra27.	5.8	280
3	Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood, 2019, 133, 1652-1663.	0.6	277
4	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood, 2019, 133, 1876-1887.	0.6	230
5	T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nature Medicine, 2019, 25, 1064-1072.	15.2	226
6	Transferred melanoma-specific CD8 ⁺ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 4592-4597.	3.3	142
7	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood, 2021, 137, 323-335.	0.6	111
8	T-Cell Therapy Using Interleukin-21â€“Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. Journal of Clinical Oncology, 2016, 34, 3787-3795.	0.8	98
9	Regression of Metastatic Merkel Cell Carcinoma Following Transfer of Polyomavirus-Specific T Cells and Therapies Capable of Reinducing HLA Class-I. Cancer Immunology Research, 2014, 2, 27-36.	1.6	89
10	Combined IL-21â€“primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. Journal of Experimental Medicine, 2016, 213, 1133-1139.	4.2	78
11	Tracking the fate and origin of clinically relevant adoptively transferred CD8 ⁺ T cells in vivo. Science Immunology, 2017, 2, .	5.6	68
12	Reâ€adapting T cells for cancer therapy: from mouse models to clinical trials. Immunological Reviews, 2014, 257, 145-164.	2.8	67
13	Immunotherapy for skin cancer. International Immunology, 2019, 31, 465-475.	1.8	47
14	HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo. Blood, 2011, 117, 5391-5402.	0.6	44
15	A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia. Blood, 2017, 130, 2410-2419.	0.6	44
16	New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies. Clinical Cancer Research, 2015, 21, 5191-5197.	3.2	29
17	The Anticancer Potential of T Cell Receptor-Engineered T Cells. Trends in Cancer, 2021, 7, 48-56.	3.8	21
18	Targeting an alternate Wilmsâ€™ tumor antigen 1 peptide bypasses immunoproteasome dependency. Science Translational Medicine, 2022, 14, eabg8070.	5.8	12

#	Article	IF	Citations
19	Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy. , 2021, 9, e002392.		9
20	EBV-Specific Donor Cells Transduced to Express a High-Affinity WT1 TCR Can Prevent Recurrence in Post-HCT Patients with High-Risk AML. Blood, 2016, 128, 1001-1001.	0.6	7
21	Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma. Journal of Investigative Dermatology, 2021, 141, 1897-1905.	0.3	6
22	Detection of engineered T cells in FFPE tissue by multiplex in situ hybridization and immunohistochemistry. Journal of Immunological Methods, 2021, 492, 112955.	0.6	1